ELC Group signs €1.5m regulatory affairs contract with Chinese pharma company

Published: 22-Apr-2015
Regulatory

Endorses its Concept to Commercialisation approach to regulatory affairs consultancy services


ELC Group, a provider of regulatory affairs services, has been awarded a €1.5m contract by one of China’s biggest pharmaceutical companies.

The company says winning the contract is a major endorsement of its Concept to Commercialisation approach, which delivers an integrated portfolio of regulatory affairs consultancy services to customers, from the development stage to clinical trials, completion of product registration, and successful marketing of the product.

The major project, which will see two products taken through ELC Group’s end-to-end service, is expected to be complete by the end of 2016. The customer, whose name is not revealed, is a top 25 Chinese pharmaceutical company and is an active ingredients company that is moving towards the finished formulation business.

ELC Group was selected for the contract following a rigorous qualification process, which compared the company against a number of other domestic and international clinical research organisations (CROs).

ELC Group CEO Marco Rubinstein said: 'This landmark contract award marks an exciting new level for us, both in size and scope of projects.'

  • Companies:
  • ELC Group
See more

You may also like

Regulatory

ELC Group expands corporate presence in Czech Republic

Read more
Major contract wins in China and US fuel latest move into larger premises in Prague

Trending Articles

  1. Overcoming CMC challenges in cell and gene therapy: part II Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  2. Overcoming CMC challenges in cell and gene therapy: part I Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
  3. Momentum in the US cannabidiol market gains retailers' attention Walmart and other big-name stores in talks with food and drinks makers in preparation for the day CBD-enriched products are allowed on the shelves
  4. Ametek Mocon achieves accreditation for analytical testing laboratory Ametek Mocon, provider of instruments and services for testing, measuring and analysing a variety of gases, has achieved ISO/IEC 17025 accreditation for its Minneapolis analytical testing laboratory
  5. Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for successful market entry from the early stages of development, reports Frederick Duynslaeger, Senior CMC Writer at Ardena

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Regulatory

ELC Group expands corporate presence in Czech Republic

Major contract wins in China and US fuel latest move into larger premises in Prague
Regulatory

ELC Group expands its offices in Ahmedabad, India

Regulatory affairs specialist continues its growth in the country
Regulatory

ELC Group opens new office in Mumbai, India

To be headed by Pooja Raj, general manager, regulatory affairs
Regulatory

ELC Group establishes global hq in Cambridge, UK

Follows year of exceptional revenue growth for regulatory affairs organisation
Regulatory

Overcoming CMC challenges in cell and gene therapy: part II

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

Overcoming CMC challenges in cell and gene therapy: part I

Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC challenges inherent in producing cell and gene therapy (CGT) drugs
Regulatory

AskBio receives FDA Fast Track Designation for congestive heart failure gene therapy programme

The fast-tracking allows the development and expedition of review processes for AB-1002, a gene therapy to promote production of a constituently active form of I-1c
Subscribe now